Loading...

Nordic Nanovector

OB:NANO
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NANO
OB
NOK2B
Market Cap
  1. Home
  2. NO
  3. Pharmaceuticals & Biotech
Company description

Nordic Nanovector ASA, a biopharmaceutical company, develops therapeutics for haematological cancers. The last earnings update was 54 days ago. More info.


Add to Portfolio Compare Print
  • Nordic Nanovector has significant price volatility in the past 3 months.
NANO Share Price and Events
7 Day Returns
3%
OB:NANO
6.9%
NO Biotechs
-0.7%
NO Market
1 Year Returns
-39.2%
OB:NANO
-36.8%
NO Biotechs
-4.7%
NO Market
NANO Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Nordic Nanovector (NANO) 3% 6.6% -22.4% -39.2% 48.7% 19.9%
NO Biotechs 6.9% 14.4% -10.6% -36.8% 65.4% -18.6%
NO Market -0.7% 2.5% -4% -4.7% 28% 12.3%
1 Year Return vs Industry and Market
  • NANO underperformed the Biotechs industry which returned -36.8% over the past year.
  • NANO underperformed the Market in Norway which returned -4.7% over the past year.
Price Volatility
NANO
Industry
5yr Volatility vs Market

Value

 Is Nordic Nanovector undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Nordic Nanovector. This is due to cash flow or dividend data being unavailable. The share price is NOK35.84.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Nordic Nanovector's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Nordic Nanovector's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OB:NANO PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in NOK NOK-6.76
OB:NANO Share Price ** OB (2019-07-16) in NOK NOK35.84
Europe Biotechs Industry PE Ratio Median Figure of 29 Publicly-Listed Biotechs Companies 21.36x
Norway Market PE Ratio Median Figure of 135 Publicly-Listed Companies 13.86x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Nordic Nanovector.

OB:NANO PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OB:NANO Share Price ÷ EPS (both in NOK)

= 35.84 ÷ -6.76

-5.3x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Nordic Nanovector is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Nordic Nanovector is loss making, we can't compare the value of its earnings to the Norway market.
Price based on expected Growth
Does Nordic Nanovector's expected growth come at a high price?
Raw Data
OB:NANO PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.3x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
47.5%per year
Europe Biotechs Industry PEG Ratio Median Figure of 23 Publicly-Listed Biotechs Companies 1.02x
Norway Market PEG Ratio Median Figure of 105 Publicly-Listed Companies 0.88x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Nordic Nanovector, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Nordic Nanovector's assets?
Raw Data
OB:NANO PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in NOK NOK8.86
OB:NANO Share Price * OB (2019-07-16) in NOK NOK35.84
Norway Biotechs Industry PB Ratio Median Figure of 7 Publicly-Listed Biotechs Companies 3.23x
Norway Market PB Ratio Median Figure of 216 Publicly-Listed Companies 1.13x
OB:NANO PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OB:NANO Share Price ÷ Book Value per Share (both in NOK)

= 35.84 ÷ 8.86

4.05x

* Primary Listing of Nordic Nanovector.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Nordic Nanovector is overvalued based on assets compared to the NO Biotechs industry average.
X
Value checks
We assess Nordic Nanovector's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Nordic Nanovector has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Nordic Nanovector expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
47.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Nordic Nanovector expected to grow at an attractive rate?
  • Nordic Nanovector's earnings growth is expected to exceed the low risk savings rate of 1.8%.
Growth vs Market Checks
  • Nordic Nanovector's earnings growth is expected to exceed the Norway market average.
  • Nordic Nanovector's revenue growth is expected to exceed the Norway market average.
Annual Growth Rates Comparison
Raw Data
OB:NANO Future Growth Rates Data Sources
Data Point Source Value (per year)
OB:NANO Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 47.5%
OB:NANO Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 69.1%
Europe Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 19.1%
Europe Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.2%
Norway Market Earnings Growth Rate Market Cap Weighted Average 14.3%
Norway Market Revenue Growth Rate Market Cap Weighted Average 3.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OB:NANO Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in NOK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OB:NANO Future Estimates Data
Date (Data in NOK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 1,827 553 852 1
2022-12-31 859 -179 -6 1
2021-12-31 126 -392 -414 2
2020-12-31 0 -400 -411 3
2019-12-31 0 -397 -368 3
OB:NANO Past Financials Data
Date (Data in NOK Millions) Revenue Cash Flow Net Income *
2019-03-31 -330 -339
2018-12-31 -327 -338
2018-09-30 0 -316 -335
2018-06-30 0 -305 -345
2018-03-31 0 -292 -329
2017-12-31 0 -249 -294
2017-09-30 0 -232 -267
2017-06-30 0 -217 -243
2017-03-31 0 -208 -227
2016-12-31 0 -204 -236
2016-09-30 0 -193 -207
2016-06-30 0 -193 -207

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Nordic Nanovector's earnings are expected to grow significantly at over 20% yearly.
  • Nordic Nanovector's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OB:NANO Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Nordic Nanovector Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OB:NANO Future Estimates Data
Date (Data in NOK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 15.30 15.30 15.30 1.00
2022-12-31 -0.10 -0.10 -0.10 1.00
2021-12-31 -7.17 -5.95 -8.40 2.00
2020-12-31 -7.52 -6.95 -8.10 2.00
2019-12-31 -7.03 -7.03 -7.03 1.00
OB:NANO Past Financials Data
Date (Data in NOK Millions) EPS *
2019-03-31 -6.76
2018-12-31 -6.88
2018-09-30 -6.83
2018-06-30 -7.04
2018-03-31 -6.70
2017-12-31 -5.99
2017-09-30 -5.55
2017-06-30 -5.16
2017-03-31 -4.95
2016-12-31 -5.26
2016-09-30 -4.65
2016-06-30 -4.64

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Nordic Nanovector will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Nordic Nanovector's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Nordic Nanovector has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Nordic Nanovector performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Nordic Nanovector's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Nordic Nanovector does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Nordic Nanovector's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Nordic Nanovector's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Nordic Nanovector's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Nordic Nanovector Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OB:NANO Past Revenue, Cash Flow and Net Income Data
Date (Data in NOK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 -338.63 77.37
2018-12-31 -337.77 70.10
2018-09-30 0.05 -334.96 75.18
2018-06-30 0.16 -345.13 75.82
2018-03-31 0.22 -328.66 72.89
2017-12-31 0.30 -293.81 75.31
2017-09-30 0.33 -267.22 74.19
2017-06-30 0.30 -242.66 69.03
2017-03-31 0.31 -227.34 62.06
2016-12-31 0.31 -235.51 57.43
2016-09-30 0.38 -207.26 51.91
2016-06-30 0.38 -206.73 50.50
2016-03-31 0.44 -203.32 49.60
2015-12-31 0.44 -173.08 48.05
2015-09-30 0.42 -168.80 43.95
2015-06-30 0.42 -118.49 32.29
2015-03-31 0.40 -86.06 25.50
2014-12-31 0.44 -63.67 17.18
2014-09-30 0.38 -45.38 9.91
2014-06-30 0.37 -38.34 7.63
2014-03-31 0.31 -26.20 5.76
2013-12-31 0.31 -17.01 3.94
2012-12-31 0.15 -13.45 4.43

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Nordic Nanovector has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Nordic Nanovector has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Nordic Nanovector improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Nordic Nanovector's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Nordic Nanovector has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Nordic Nanovector's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Nordic Nanovector's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Nordic Nanovector is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Nordic Nanovector's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Nordic Nanovector's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Nordic Nanovector has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Nordic Nanovector Company Filings, last reported 3 months ago.

OB:NANO Past Debt and Equity Data
Date (Data in NOK Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 484.51 0.00 538.50
2018-12-31 363.19 0.00 440.07
2018-09-30 440.29 0.00 499.65
2018-06-30 510.41 0.00 570.13
2018-03-31 594.18 0.00 641.53
2017-12-31 679.61 0.00 756.57
2017-09-30 761.22 0.00 803.74
2017-06-30 840.50 0.00 881.41
2017-03-31 900.22 0.00 933.32
2016-12-31 949.29 0.00 1,018.22
2016-09-30 541.35 0.00 560.08
2016-06-30 601.02 0.00 618.42
2016-03-31 650.34 0.00 671.89
2015-12-31 712.74 0.00 743.37
2015-09-30 742.67 0.00 769.46
2015-06-30 800.58 0.00 817.14
2015-03-31 771.37 0.00 781.41
2014-12-31 330.21 0.00 337.02
2014-09-30 330.13 0.00 329.52
2014-06-30 52.21 0.00 51.65
2014-03-31 67.99 0.00 67.69
2013-12-31 78.79 0.00 79.57
2012-12-31 7.68 0.00 6.67
  • Nordic Nanovector has no debt.
  • Nordic Nanovector has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Nordic Nanovector has sufficient cash runway for 1.6 years based on current free cash flow.
  • Nordic Nanovector has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 22.5% each year.
X
Financial health checks
We assess Nordic Nanovector's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Nordic Nanovector has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Nordic Nanovector's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Nordic Nanovector dividends. Estimated to be 0% next year.
If you bought NOK2,000 of Nordic Nanovector shares you are expected to receive NOK0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Nordic Nanovector's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Nordic Nanovector's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OB:NANO Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.8%
Norway Market Average Dividend Yield Market Cap Weighted Average of 110 Stocks 4.4%
Norway Minimum Threshold Dividend Yield 10th Percentile 1.9%
Norway Bottom 25% Dividend Yield 25th Percentile 2.4%
Norway Top 25% Dividend Yield 75th Percentile 6.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OB:NANO Future Dividends Estimate Data
Date (Data in NOK) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Nordic Nanovector has not reported any payouts.
  • Unable to verify if Nordic Nanovector's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Nordic Nanovector's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Nordic Nanovector has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Nordic Nanovector's dividends in 3 years as they are not expected to pay a notable one for Norway.
X
Income/ dividend checks
We assess Nordic Nanovector's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Nordic Nanovector afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Nordic Nanovector has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Nordic Nanovector's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Eduardo Bravo
COMPENSATION NOK9,412,000
AGE 54
TENURE AS CEO 1 years
CEO Bio

Mr. Eduardo Bravo is Chief Executive Officer of Nordic Nanovector ASA since July 2, 2018. He has more than 25 years of experience in the biopharmaceutical industry and a strong track record in leading and growing international biotech and pharmaceutical organisations. He served as Chief Executive Officer of TiGenix Since 2011. Prior to joining TiGenix' predecessor, Cellerix, in 2005, he held several senior management positions at Sanofi-Aventis and SmithKline Beecham. He serves as Chairman of Vivet Therapeutics. He holds a degree in Business Administration and an MBA (INSEAD).

CEO Compensation
  • Insufficient data for Eduardo to compare compensation growth.
  • Eduardo's remuneration is higher than average for companies of similar size in Norway.
Management Team Tenure

Average tenure and age of the Nordic Nanovector management team in years:

1.5
Average Tenure
52.5
Average Age
  • The average tenure for the Nordic Nanovector management team is less than 2 years, this suggests a new team.
Management Team

Eduardo Bravo

TITLE
Chief Executive Officer
COMPENSATION
NOK9M
AGE
54
TENURE
1 yrs

Tone Kvåle

TITLE
Chief Financial Officer
COMPENSATION
NOK3M
AGE
50
TENURE
6.7 yrs

Marco Renoldi

TITLE
Chief Operating Officer
COMPENSATION
NOK4M
AGE
62
TENURE
3.1 yrs

Jostein Dahle

TITLE
Chief Scientific Officer
COMPENSATION
NOK2M
AGE
46

Malene Brondberg

TITLE
Vice President of Investor Relations & Corporate Communications
COMPENSATION
NOK3M
AGE
46
TENURE
1.4 yrs

Rita Dege

TITLE
Chief Human Resources Officer
COMPENSATION
NOK2M
AGE
52

Lisa Rojkjaer

TITLE
Chief Medical Officer
COMPENSATION
NOK4M
AGE
53
TENURE
2.7 yrs

Rosemarie Corrigan

TITLE
Chief Quality Officer
COMPENSATION
NOK3M
AGE
54
TENURE
1.6 yrs

Fredrik Haavind

TITLE
Head of Legal & Compliance
TENURE
0.3 yrs

Maureen Deehan

TITLE
Head of Corporate Development & Strategy
TENURE
1.1 yrs
Board of Directors Tenure

Average tenure and age of the Nordic Nanovector board of directors in years:

4.2
Average Tenure
59.5
Average Age
  • The tenure for the Nordic Nanovector board of directors is about average.
Board of Directors

Jan Egberts

TITLE
Chairman of the Board
AGE
61
TENURE
0.4 yrs

Per Anders Samuelsson

TITLE
Director
COMPENSATION
NOK345K
AGE
58
TENURE
4.7 yrs

Hilde Furberg

TITLE
Director
COMPENSATION
NOK345K
AGE
53
TENURE
4.7 yrs

Timothy Illidge

TITLE
Chairman of Scientific Advisory Board
TENURE
4.2 yrs

Pierluigi Zinzani

TITLE
Chairman of Scientific Advisory Board
TENURE
4.2 yrs

Mark Kaminski

TITLE
Member of Scientific Advisory Board & Member of Clinical Advisory Board

Gisela Schwab

TITLE
Director
COMPENSATION
NOK305K
AGE
62
TENURE
4.3 yrs

Arne Kolstad

TITLE
Member of Scientific Advisory Board
TENURE
4.2 yrs

Dolores Caballero

TITLE
Member of Scientific Advisory Board
TENURE
4.2 yrs

Stephen Schuster

TITLE
Member of Scientific Advisory Board
TENURE
4.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (NOK) Value (NOK)
X
Management checks
We assess Nordic Nanovector's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Nordic Nanovector has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

What Should You Know About The Future Of Nordic Nanovector ASA's (OB:NANO)?

Nordic Nanovector ASA's (OB:NANO) most recent earnings update in December 2018 showed that losses became smaller relative to the prior year's level - great news for investors Investors may find it useful to understand how market analysts predict Nordic Nanovector's earnings growth outlook over the next few years and whether the future looks brighter. … OB:NANO Past and Future Earnings, May 22nd 2019 While it is helpful to understand the growth year by year relative to today’s level, it may be more beneficial analyzing the rate at which the business is moving on average every year. … Future Earnings: How does NANO's growth rate compare to its peers and the wider market?

Simply Wall St -

Nordic Nanovector (OB:NANO) Shareholders Booked A 89% Gain In The Last Three Years

For example, the Nordic Nanovector ASA (OB:NANO) share price is up 89% in the last three years, clearly besting than the market return of around 30% (not including dividends). … Of course, if you time it right, high risk investments like this can really pay off, as Nordic Nanovector investors might know. … Given the share price has increased by a solid 24% per year, over 3 years, its fair to say investors remain excited about the future, despite the potential need for cash.

Simply Wall St -

Could The Nordic Nanovector ASA (OB:NANO) Ownership Structure Tell Us Something Useful?

The big shareholder groups in Nordic Nanovector ASA (OB:NANO) have power over the company. … With a market capitalization of øre2.6b, Nordic Nanovector is a small cap stock, so it might not be well known by many institutional investors. … Taking a look at the our data on the ownership groups (below), it's seems that.

Simply Wall St -

Nordic Nanovector ASA (OB:NANO) Insiders Have Been Selling

So shareholders might well want to know whether insiders have been buying or selling shares in Nordic Nanovector ASA (OB:NANO). … Nordic Nanovector Insider Transactions Over The Last Year. … In the last twelve months, the biggest single sale by an insider was when Luigi Costa sold øre436k worth of shares at a price of øre43.56 per share.

Simply Wall St -

Is Nordic Nanovector ASA's (OB:NANO) Balance Sheet Strong Enough To Weather A Storm?

The direct benefit for Nordic Nanovector ASA (OB:NANO), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … However, the trade-off is NANO will have to adhere to stricter debt covenants and have less financial flexibility. … Is NANO growing fast enough to value financial flexibility over lower cost of capital.

Simply Wall St -

Is Nordic Nanovector ASA's (OB:NANO) Balance Sheet A Threat To Its Future?

However, it also faces higher cost of capital given interest cost is generally lower than equity. … Does NANO's growth rate justify its decision for financial flexibility over lower cost of capital … Debt capital generally has lower cost of capital compared to equity funding.

Simply Wall St -

Does Nordic Nanovector ASA (OB:NANO) Go Up With The Market?

A widely-used metric to measure a stock's market risk is beta, and the broad market index represents a beta value of one. … Check out our latest analysis for Nordic Nanovector An interpretation of NANO's beta Nordic Nanovector's beta of 0.03 indicates that the stock value will be less variable compared to the whole stock market. … Based on this beta value, NANO appears to be a stock that an investor with a high-beta portfolio would look for to reduce risk exposure to the market.

Simply Wall St -

Should You Be Concerned About Nordic Nanovector ASA's (OB:NANO) Shareholders?

Today, I will be analyzing Nordic Nanovector ASA’s (OB:NANO) recent ownership structure, an important but not-so-popular subject among individual investors. … Check out our latest analysis for Nordic Nanovector OB:NANO Ownership_summary Mar 31st 18 Institutional Ownership Institutions account for 24.66% of NANO's outstanding shares, a significant enough holding to move stock prices if they start buying and selling in large quantities, especially when there are relatively small amounts of shares available on the market to trade. … Thus, investors should dig deeper into NANO's business relations with these companies and how it can affect shareholder returns in the long-term.Next Steps: NANO's considerably high level of institutional ownership calls for further analysis into its margin of safety.

Simply Wall St -

When Will Nordic Nanovector ASA (OB:NANO) Breakeven?

View our latest analysis for Nordic Nanovector According to the industry analysts covering NANO, breakeven is near. … What rate will NANO have to grow year-on-year in order to breakeven on this date? … Next Steps: There are too many aspects of NANO to cover in one brief article, but the key fundamentals for the company can all be found in one place – NANO’s company page on Simply Wall St.

Simply Wall St -

Nordic Nanovector ASA (OB:NANO): What Are The Future Prospects?

In December 2017, Nordic Nanovector ASA (OB:NANO) released its most recent earnings announcement, which showed that losses became smaller relative to the prrior year's level - great news for investors Below, I've laid out key numbers on how market analysts view Nordic Nanovector's earnings growth trajectory over the next few years and whether the future looks brighter. … OB:NANO Future Profit Mar 16th 18 Although it is informative understanding the growth each year relative to today’s level, it may be more beneficial determining the rate at which the earnings are growing every year, on average. … This means that, we can anticipate Nordic Nanovector will grow its earnings by 34.54% every year for the next few years.

Simply Wall St -

Company Info

Description

Nordic Nanovector ASA, a biopharmaceutical company, develops therapeutics for haematological cancers. Its lead clinical-stage product candidate is Betalutin, an antibody-radionuclide-conjugate, which is in Phase I/II clinical trial for the treatment of patients with non-hodgkin lymphoma, a life-threatening blood cancer. Nordic Nanovector ASA has research collaborations with INSERM; Dana Farber; Paul Scherrer Institute; Heidelberg Pharma; LegoChemBio; OranoMed; IOR cancer institute; Norwegian Radium Hospital; University of Bergen; and UMCG. The company was formerly known as Nordic Nanovector AS and changed its name to Nordic Nanovector ASA in 2014. Nordic Nanovector ASA was founded in 2009 and is headquartered in Oslo, Norway.

Details
Name: Nordic Nanovector ASA
NANO
Exchange: OB
Founded: 2009
NOK1,975,274,864
55,113,696
Website: http://www.nordicnanovector.com
Address: Nordic Nanovector ASA
Kjelsåsveien 168 B,
Oslo,
Oslo, 884,
Norway
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OB NANO Ordinary Shares Oslo Bors NO NOK 08. Jul 2014
DB 8NN Ordinary Shares Deutsche Boerse AG DE EUR 08. Jul 2014
LSE 0R6Y Ordinary Shares London Stock Exchange GB NOK 08. Jul 2014
BATS-CHIXE NANOO Ordinary Shares BATS 'Chi-X Europe' GB NOK 08. Jul 2014
Number of employees
Current staff
Staff numbers
45
Nordic Nanovector employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/16 21:33
End of day share price update: 2019/07/16 00:00
Last estimates confirmation: 2019/05/29
Last earnings filing: 2019/05/23
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.